In contrast to short-acting dihydropyridine calcium antagonists, heart
-rate lowering calcium antagonists have been shown to be beneficial in
some patients for prevention of reinfarction. The study of Hansen et
al in this present issue shows that the addition of verapamil to trand
olapril reduces event rates by >60% in patients after myocardial infar
ction who are in congestive heart failure. These findings are provacat
ive and should be corroborated in a perspective, randomized trial.